Esketamine Market Report 2026

The esketamine market size has grown rapidly in recent years. It will grow from $1.51 billion in 2025 to $1.67 billion in 2026 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to unmet needs in major depressive disorder, limitations of traditional antidepressants, regulatory approvals for nasal esketamine, rising mental health awareness, expansion of specialty psychiatric clinics.

The esketamine market size is expected to see rapid growth in the next few years. It will grow to $2.5 billion in 2030 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to increasing prevalence of treatment-resistant depression, demand for fast-acting therapies, expansion of supervised outpatient administration, growing mental health infrastructure, continued clinical research investment. Major trends in the forecast period include growing adoption for treatment-resistant depression, expansion of nasal spray administration, rising use in acute psychiatric care settings, increased monitoring and controlled distribution, growing research into rapid-acting antidepressants.

The rising prevalence of treatment-resistant depression (TRD) is anticipated to drive the growth of the esketamine market in the coming years. Treatment-resistant depression (TRD) is defined as depression that does not improve after trying at least two different antidepressant medications at adequate doses for a sufficient period. TRD is increasing due to the limited effectiveness of conventional antidepressants, resulting in prolonged and recurrent depressive episodes. Esketamine addresses treatment-resistant depression (TRD) by providing a rapid-acting mechanism that targets NMDA receptors, delivering relief for patients unresponsive to traditional antidepressants. For example, in September 2023, the National Institute of Mental Health (NIMH), a U.S.-based federal agency, reported that approximately 30% of individuals with major depressive disorder in the U.S. are resistant to standard treatments. Consequently, the growing incidence of treatment-resistant depression is fueling the expansion of the esketamine market.

Major companies operating in the esketamine market are concentrating on developing innovative treatment options, such as monotherapy, to provide depressive symptom relief beyond what placebo can achieve. Monotherapy involves using a single drug or treatment to manage a disease or medical condition, rather than combining multiple therapies. For example, in January 2025, Johnson & Johnson, a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved SPRAVATO (esketamine) as the first and only monotherapy for adults with treatment-resistant depression (TRD). Supported by clinical studies, the approval showed that SPRAVATO could rapidly reduce depressive symptoms, with notable improvements observed within 24 hours. This development offers a crucial option for about 30% of individuals who do not respond to conventional antidepressants, removing the need for additional oral medications. Although SPRAVATO has a favorable safety profile, it is administered under a Risk Evaluation and Mitigation Strategy (REMS) to manage potential side effects. This achievement represents a significant step forward in TRD treatment, providing renewed hope for better patient outcomes.

In April 2024, Celon Pharma S.A., a pharmaceutical company based in Poland, partnered with Tang Capital Management LLC to form Novohale Therapeutics, LLC. This partnership aims to progress the development of Falkieri, an esketamine dry powder inhalation product, into global Phase 3 clinical trials for bipolar depression. Tang Capital Management LLC is a US-based firm specializing in life sciences and biotechnology.

Major companies operating in the esketamine market are Johnson & Johnson, Janssen Pharmaceuticals, Sage Therapeutics Inc., VistaGen Therapeutics Inc., Cerecor Inc., Celon Pharma S.A., Hikma Pharmaceuticals plc, Seqens Group, Arevipharma GmbH, Nortec Química S.A., Supriya Lifescience Ltd., Maithri Drugs Pvt. Ltd., SynZeal Research Pvt. Ltd., XWPharma Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Aurobindo Pharma Ltd., H. Lundbeck A/S, Otsuka Pharmaceutical Co. Ltd.

North America was the largest region in the esketamine market in 2025. The regions covered in the esketamine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the esketamine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the esketamine market by increasing the cost of imported active pharmaceutical ingredients, formulation intermediates, and specialized delivery system components used in nasal antidepressant therapies. These impacts have been most pronounced in branded nasal spray segments, particularly in north america and europe where production relies on global supply chains. Asia-pacific manufacturers have faced supply delays and cost pressures due to import dependencies. However, tariffs have encouraged localized manufacturing and regional formulation capacity expansion, supporting treatment availability.

The esketamine market research report is one of a series of new reports that provides esketamine market statistics, including esketamine industry global market size, regional shares, competitors with a esketamine market share, detailed esketamine market segments, market trends and opportunities, and any further data you may need to thrive in the esketamine industry. This esketamine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Esketamine is a fast-acting anesthetic and antidepressant derived from ketamine, recognized for its NMDA receptor antagonist effects. It is employed for treatment-resistant depression and major depressive disorder with suicidal thoughts, and is administered as a nasal spray under medical supervision.

The primary forms of esketamine include oral medications, injections, nasal sprays, and others. Oral medications consist of pills or tablets containing esketamine, which are taken by mouth to manage various conditions such as depression. The range of indications includes major depressive disorder, chronic pain, post-traumatic stress disorder, and anxiety disorders. The patient groups involved are adult patients, pediatric patients, and geriatric patients. Its applications include use as a general anesthetic and for treatment-resistant depression, and it is distributed through multiple channels such as hospital pharmacies, online pharmacies, and retail pharmacies.

The esketamine market consists of sales of products including spravato, and esketamine injectable formulations. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.